Entrada Therapeutics reports positive first-cohort results in Phase 1/2 DMD study
The company announced positive results from the first cohort of participants with Duchenne muscular dystrophy in the Phase 1/2 ELEVATE-45-201 study of ENTR-601-45.
Story updates
11:03:25 AM UTC
SquawkNews
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45